Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 31.91

+2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Daniel Shaffer who wrote (297)	11/17/1997 5:30:00 PM
From: Douglas	Read Replies (2) of 455

Here is part of the Harvard connection: Ellis L. Reinherz, M.D. is a founder of Procept and has served as Chairman of its Scientific Advisory Board since October 1985. Since 1984, he has served as Chief,Laboratory of Immunobiology at the Dana-Farber Cancer Institute and as Professor of Medicine at Harvard Medical School. He received his M.D. from Harvard Medical School in 1975. Dr. Reinherz serves on the editorial and review boards of key medical and scientific publications in hematology and immunology. Reference your question "is it that their PR is so lousy". I would have to say that they don't utilize everything available to them. Don't know if they are afraid of potential lawsuits, but being too conservative can lead to a lower stock price! Procept is a good example. Should be coming out soon with new financing or a going out of business sign. My bet is on preferred stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next